Navigation Links
Pacific Shore Holdings, Inc. Receives Symbol Change Approval From FINRA
Date:2/14/2011

LOS ANGELES, Feb 14, 2011 /PRNewswire/ -- Pacific Shore Holdings, Inc. (previously Green Shores, Inc.), a Delaware corporation, announced today that management has received approval from the Financial Industry Regulatory Authority ("FINRA") for the change of its symbol to "PSHR.PK" from "GSHR.PK". "We are excited about the symbol change, as it takes us one step closer to completion of our planned entrance into the Public Markets. "Once we enter the Public Marketplace, we believe that we will be in position to attract significant capital infusions from a multitude of Market players," states Pacific Shore Holdings, Inc. Chief Financial Officer Ronald J. Tchorzewski.

Building on its corporate governance, Pacific Shore Holdings, Inc. also announced today that it has appointed Matthew A. Mills as Chairman of the Board, President and Chief Executive Officer of the Company replacing Dr. David E. Toomey who will remain as a Director of the Company as well as Executive Vice President. In addition, Mr. Mills announced the appointments of Ronald J. Tchorzewski as Chief Financial Officer and Director, Jennifer Mills as Corporate Secretary and Director and Dr. Allan Kurtz as a Director. "I am pleased with these appointments as each individual brings with them valuable experience and expertise to help take our Company to the next level. Our multiple brands and products have shown a very positive response from consumers around the world during our test marketing programs. I believe we will now be poised to secure the financial resources necessary to begin aggressive product marketing campaigns nationally and internationally to successfully expand our operations," states President and Chief Executive Officer Matthew Mills.

About Pacific Shore Holdings, Inc.: Pacific Shore Holdings, Inc. is a Delaware corporation whose dormant common stock has a trading symbol on the Pink Sheets of "PSHR.PK" which was previously "GSHR.PK". For more information, contact Pacific Shore Holdings, Inc. at info@pac-sh.com or (818) 998-0996.

Forward-Looking Statements: Certain statements in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events.


'/>"/>
SOURCE Pacific Shore Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen
2. Asia Pacific Flexible Alternating Current Transmission Equipment Markets
3. BioProcess International Launches Monthly Asia-Pacific eNewsletter
4. Sundia Named Deloitte Technology Fast 500 Asia Pacific for 2nd Consecutive Year
5. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
6. Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit
7. Pacific Biometrics Completes $4 Million Debt Financing
8. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
9. Pacific Health Research Institute Awarded $2.8 Million in Research Funding
10. PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial
11. Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, ... developing a new category of therapeutics, announced today the ... SB-030 in peripheral artery disease. The trial will evaluate ... single-use therapeutic, in the reduction of restenosis following angioplasty. ... critical development milestone for SB-030," said Nathan Bachtell ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
Breaking Biology News(10 mins):